Asunercept

Drug Profile

Asunercept

Alternative Names: APG-101; Apocept; Asinercept; Asinerceptum; Asunerceptum; CAN-008; CD95-Fc fusion protein; Fas-Fc fusion protein

Latest Information Update: 30 May 2017

Price : $50

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Life Sciences
  • Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Glioblastoma; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Myelodysplastic syndromes
  • Preclinical Solid tumours
  • No development reported Graft-versus-host disease; Myocardial infarction; Stroke

Most Recent Events

  • 29 May 2017 Asunercept receives Priority Medicine (PRIME) status for Glioblastoma in European Union
  • 23 May 2017 CANbridge Life Sciences plans a phase II trial for Glioblastoma in China
  • 16 May 2017 University Hospital Heidelberg plans a phase I/II trial in Glioblastoma (Newly diagnosed) in Germany (NCT03158389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top